Glaukos (NYSE:GKOS) Director Leana Wen Sells 525 Shares

Glaukos Corporation (NYSE:GKOS) Director Leana Wen sold 525 shares of the stock in a transaction dated Friday, July 31st. The stock was sold at an average price of $167.63, for a total value of $88,005.75. Following the sale, the director owned 21,092 shares of the company’s stock, valued at approximately $3,535,651.96. The trade was a 2.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Glaukos Trading Up 2.5%

Shares of Glaukos stock traded up $4.18 on Monday, hitting $170.90. 1,108,283 shares of the company’s stock traded hands, compared to its average volume of 890,718. Glaukos Corporation has a one year low of $73.16 and a one year high of $184.00. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.04 and a quick ratio of 4.46. The company has a fifty day moving average of $138.11 and a two-hundred day moving average of $125.17. The company has a market capitalization of $10.08 billion, a price-to-earnings ratio of -52.59 and a beta of 0.78.

Glaukos (NYSE:GKOS) last released its earnings results on Wednesday, July 29th. The medical instruments supplier reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.07. The business had revenue of $185.61 million during the quarter, compared to analysts’ expectations of $150.93 million. Glaukos had a negative return on equity of 6.37% and a negative net margin of 30.68%.The firm’s revenue was up 49.6% on a year-over-year basis. During the same quarter last year, the firm posted ($0.24) earnings per share. As a group, sell-side analysts expect that Glaukos Corporation will post -0.41 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have recently commented on GKOS shares. William Blair reaffirmed an “outperform” rating on shares of Glaukos in a research report on Tuesday, May 26th. JPMorgan Chase & Co. increased their target price on shares of Glaukos from $120.00 to $140.00 and gave the stock an “overweight” rating in a research note on Thursday, April 30th. UBS Group assumed coverage on shares of Glaukos in a research note on Tuesday, July 28th. They set a “neutral” rating and a $150.00 target price on the stock. Needham & Company LLC raised their price target on shares of Glaukos from $150.00 to $201.00 and gave the stock a “buy” rating in a report on Thursday. Finally, Citigroup lifted their price target on shares of Glaukos from $175.00 to $188.00 and gave the company a “buy” rating in a research note on Thursday. Twelve investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $177.33.

Institutional Investors Weigh In On Glaukos

A number of hedge funds have recently added to or reduced their stakes in the company. First Horizon Corp increased its holdings in shares of Glaukos by 1,715.4% during the fourth quarter. First Horizon Corp now owns 236 shares of the medical instruments supplier’s stock valued at $27,000 after acquiring an additional 223 shares in the last quarter. Los Angeles Capital Management LLC bought a new position in shares of Glaukos in the 4th quarter worth $28,000. Larson Financial Group LLC lifted its holdings in shares of Glaukos by 62.0% in the 4th quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier’s stock worth $39,000 after purchasing an additional 132 shares in the last quarter. Parallel Advisors LLC grew its position in Glaukos by 159.2% in the 1st quarter. Parallel Advisors LLC now owns 368 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 226 shares during the period. Finally, Farther Finance Advisors LLC grew its position in Glaukos by 111.4% in the 4th quarter. Farther Finance Advisors LLC now owns 408 shares of the medical instruments supplier’s stock valued at $46,000 after purchasing an additional 215 shares during the period. Institutional investors and hedge funds own 99.04% of the company’s stock.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.